By Billy Candra 
Cambridge, UK – A groundbreaking study led by researchers at the University of Cambridge has provided compelling evidence that bilateral salpingo-oophorectomy (BSO), the surgical removal of ovaries and fallopian tubes, is associated with a substantial reduction in the risk of early death and the development of second cancers among women diagnosed with breast cancer who carry specific BRCA1 and BRCA2 genetic variants. The findings, published recently in The Lancet Oncology, offer crucial insights for clinical guidance and patient counseling, particularly by allaying long-standing concerns about potential adverse side-effects associated with the procedure.
The study addresses a critical knowledge gap, as previous research primarily focused on BSO’s efficacy in reducing ovarian cancer risk. While an 80% reduction in ovarian cancer incidence has been well-established, the broader impact on overall survival and the development of other health conditions, especially for women with a prior breast cancer diagnosis, remained less clear. This uncertainty stemmed from the ethical impossibility of conducting randomized controlled trials (RCTs) in this high-risk population, which would entail withholding a known risk-reducing intervention from a control group.
Understanding the Genetic Imperative: BRCA1 and BRCA2
The BRCA1 (BReast CAncer gene 1) and BRCA2 (BReast CAncer gene 2) genes are human genes that produce proteins responsible for repairing damaged DNA. As such, they are classified as tumor suppressor genes. When these genes are mutated, or altered, they can no longer effectively repair DNA, leading to an increased risk of developing certain cancers, most notably breast and ovarian cancers. The discovery of BRCA1 in 1990 and BRCA2 in 1994 revolutionized cancer genetics, paving the way for genetic testing and personalized risk management strategies.
For women carrying a pathogenic variant (PV) in BRCA1, the lifetime risk of developing breast cancer can be as high as 45-85%, and the lifetime risk of ovarian cancer can range from 20-45%. For BRCA2 PV carriers, the breast cancer risk is similarly elevated (45-85%), with an ovarian cancer risk of 10-20%. These figures represent a stark contrast to the general population’s lifetime risks, which are approximately 13% for breast cancer and less than 1.5% for ovarian cancer. Ovarian cancer, in particular, is notoriously difficult to detect early due to vague symptoms, often leading to diagnosis at advanced stages with a poor prognosis. This makes effective risk reduction strategies paramount.
Current clinical guidelines recommend that women with BRCA1 PVs consider BSO between the ages of 35 and 40, or upon completion of childbearing. For BRCA2 PV carriers, the recommended age range for the procedure is slightly later, between 40 and 45. These age ranges are strategically chosen to balance the benefits of risk reduction against the potential impact of premature menopause.
Navigating Ethical Dilemmas Through Innovative Research
The ethical constraints surrounding RCTs for BSO in BRCA carriers necessitated an alternative research approach. The Cambridge team, in collaboration with the National Disease Registration Service (NDRS) in NHS England, ingeniously leveraged the power of electronic health records and data from NHS genetic testing laboratories. This allowed them to conduct a large-scale, observational study, examining the long-term outcomes of BSO among BRCA1 and BRCA2 PV carriers already diagnosed with breast cancer. This methodology represents a significant advancement in real-world evidence generation, showcasing the immense value of robust, curated national health datasets.
Professor Antonis Antoniou, from the Department of Public Health and Primary Care and the study’s senior author, emphasized this point, stating, "The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research." This approach provides a blueprint for investigating complex health questions where traditional randomized trials are not feasible.
Key Findings: A Clear Survival Advantage and No Serious Side-Effects
The study identified a cohort of 3,400 women, approximately 1,700 for each BRCA variant, all with a prior diagnosis of breast cancer. Of these, around 850 BRCA1 carriers and 1,000 BRCA2 carriers had undergone BSO surgery. The median follow-up period for the study was 5.5 years, a substantial duration for observing critical health outcomes.
The results were profoundly reassuring:
- Reduced Early Mortality: Women who underwent BSO were approximately half as likely to die from cancer or any other cause during the follow-up period. This reduction was more pronounced in BRCA2 carriers (a 56% reduction) compared to BRCA1 carriers (a 38% reduction). While the researchers prudently state that 100% certainty regarding causality is impossible in an observational study, the strength of the evidence strongly points towards BSO as the driving factor.
- Lower Risk of Second Cancers: Beyond the primary cancer diagnosis, women who had BSO also exhibited an approximately 40% lower risk of developing a second primary cancer. This finding underscores the systemic protective effects potentially offered by the removal of estrogen-producing organs.
- Absence of Adverse Long-Term Outcomes: Crucially, the study found no link between BSO and an increased risk of other long-term conditions such as heart disease, stroke, or depression. This directly contrasts with some previous studies conducted in the general population, which suggested an association between early menopause (whether surgical or natural) and increased risk of these conditions. The specific genetic profile of BRCA carriers, or perhaps the close medical surveillance they receive, may play a role in this observed difference.
Hend Hassan, the first author and a PhD student at the Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, and Wolfson College, Cambridge, articulated the significance of these findings: "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes. Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression."
Addressing the Elephant in the Room: Early Menopause and HRT
The primary concern associated with BSO is the immediate onset of surgical menopause. This can lead to a range of symptoms including hot flashes, night sweats, vaginal dryness, mood swings, and potentially long-term effects on bone density (osteoporosis) and cardiovascular health due to the abrupt cessation of estrogen production. For many women undergoing BSO, hormone replacement therapy (HRT) can mitigate these symptoms and associated risks.
However, for BRCA1 and BRCA2 carriers with a history of breast cancer, HRT often presents a complex dilemma. Estrogen-receptor-positive breast cancers are fueled by estrogen, making HRT a potential contraindication that could increase the risk of recurrence. This study’s finding that BSO did not increase the risk of heart disease, stroke, or depression in this specific population is particularly reassuring for women who may not be candidates for HRT and have previously faced agonizing choices regarding their health management. It provides a more complete picture of the net benefit, even in the absence of estrogen replacement.
Unsettling Disparities in Surgical Uptake
Despite the clear benefits, the study also unveiled concerning disparities in the uptake of BSO. The data indicated that most women undergoing BSO were white, with Black and Asian women being approximately half as likely to undergo the procedure compared to their white counterparts. Furthermore, women residing in less deprived areas were more likely to have BSO than those in the most deprived categories.
These findings highlight potential systemic inequities in healthcare access, awareness, and shared decision-making. Hend Hassan commented on this disparity, stating, "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it. We need to understand why this is and encourage uptake among these women."
Several factors could contribute to these disparities:
- Awareness and Education: Unequal access to genetic counseling and information about risk-reducing surgeries.
- Cultural Factors: Varying cultural perspectives on surgery, family planning, and body image.
- Socioeconomic Barriers: Financial constraints, lack of insurance coverage, time off work for surgery and recovery, and limited access to specialized care.
- Healthcare Provider Bias: Unconscious biases in counseling or referral patterns.
- Language Barriers: Difficulties in understanding complex medical information.
Addressing these disparities will require targeted public health campaigns, improved access to culturally competent genetic counseling, and systemic efforts to reduce socioeconomic barriers to care.
Implications for Clinical Practice and Patient Empowerment
The robust findings of this study are poised to significantly impact clinical guidelines and the counseling of women carrying BRCA1 and BRCA2 pathogenic variants, especially those with a history of breast cancer. Professor Antonis Antoniou noted, "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation."
This research provides concrete data to support the recommendation of BSO, offering a clearer picture of not just ovarian cancer risk reduction, but also broader survival benefits and the absence of specific long-term adverse health outcomes. Genetic counselors and oncologists can now present a more comprehensive risk-benefit profile to their patients, empowering them to make highly personal and informed decisions about their health trajectory. The evidence strengthens the argument for BSO as a life-extending and health-preserving intervention in this specific high-risk group.
The Future of Cancer Research: Data-Driven Detection and Beyond
The success of this study underscores the transformative potential of large-scale, real-world data in advancing medical research. The National Disease Registration Service (NDRS) plays a vital role in collecting and curating the comprehensive health data that made this research possible. Such datasets are instrumental in understanding disease patterns, evaluating interventions, and informing public health policy on a population level.
Looking ahead, further research will undoubtedly build upon these findings. Longer follow-up periods will be essential to confirm the sustained absence of adverse effects and to precisely quantify the long-term survival benefits. Studies focusing on the mechanisms behind the reduced risk of second cancers could also yield valuable insights into cancer biology. Moreover, research into the specific drivers of the observed disparities in BSO uptake is critical to ensure equitable access to life-saving interventions.
The University of Cambridge, alongside Addenbrooke’s Charitable Trust (ACT), is actively fundraising for a new hospital, the Cambridge Cancer Research Hospital. This facility, a partnership with Cambridge University Hospitals NHS Foundation Trust, aims to revolutionize cancer diagnosis and treatment for patients across the East of England and beyond. Research such as this latest study exemplifies the kind of impactful, clinically relevant work that will be further propelled by such advanced infrastructure, promising to change the lives of cancer patients globally.
This vital research was generously funded by Cancer Research UK, with additional support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, highlighting the collaborative effort required to tackle complex health challenges and improve patient outcomes. The study’s clear and reassuring results provide a powerful testament to the efficacy of BSO, cementing its role as a critical intervention in the personalized management of breast cancer patients carrying BRCA1 and BRCA2 genetic variants.
